Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with diabetes mellitus and non-ST-segment elevation myocardial infarction who underwent successful percutaneous coronary intervention

Other Korea Acute Myocardial Infarction Registry (KAMIR) investigators

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background and aims: Angiotensin-converting-enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB) are known to be beneficial for either non-ST-segment elevation myocardial infarction (NSTEMI) patients or diabetes mellitus (DM) patients. However, the comparative efficacy of ACEI versus ARB in patients with NSTEMI and DM is unclear. The aim of this study was to compare the protective efficacy of ACEI versus ARB in patients with NSTEMI and DM, who underwent percutaneous coronary intervention (PCI) with drug-eluting stents (DES). Methods: Among 53,281 patients enrolled in the nationwide Korea Acute Myocardial Infarction Registry, 3426 patients with NSTEMI and DM, who were treated with renin-angiotensin system (RAS) inhibitors, had undergone successful PCI with DESs. They were classified into two groups: ACEI group (N = 2076), and ARB group (N = 1350). Individual major clinical outcomes and major adverse cardiac events (MACE), the composite of total death, myocardial infarction (MI), and revascularization were compared between the two groups for up to two years. Results: After propensity score-matching analysis, two propensity-matched groups (1103 pairs, total = 2206) were generated, and the baseline characteristics were balanced. Although all causes of death and recurrent MI were not different between the two groups, the incidence of revascularization (4.0% vs. 7.1%; p = 0.002), including target vessel (2.3% vs. 5.0; p = 0.002), and MACE (8.7% vs. 12.5%, p = 0.008), were lower in the ACEI group than the ARB group at two-year follow-up. Conclusions: Compared with ARB, no beneficial effects of ACEI on all causes of death, cardiac death, or recurrence of MI were observed, but ACEI reduced the incidence of revascularization and MACE in this population. Thus, well-designed trials with a larger population are needed to confirm these results.

Original languageEnglish
Pages (from-to)130-135
Number of pages6
JournalAtherosclerosis
Volume277
DOIs
Publication statusPublished - 2018 Oct 1

Fingerprint

Angiotensin Receptor Antagonists
Percutaneous Coronary Intervention
Angiotensin-Converting Enzyme Inhibitors
Diabetes Mellitus
Myocardial Infarction
Cause of Death
Propensity Score
Myocardial Revascularization
Drug-Eluting Stents
Incidence
Korea
Renin-Angiotensin System
Non-ST Elevated Myocardial Infarction
Population
Registries
Research Design
Recurrence

Keywords

  • Angiotensin II receptor blockers
  • Angiotensin-converting-enzyme inhibitors
  • Diabetes mellitus
  • Myocardial infarction
  • Non-ST-Segment elevation myocardial infarction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{317106d05ee842878396fe1063b57613,
title = "Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with diabetes mellitus and non-ST-segment elevation myocardial infarction who underwent successful percutaneous coronary intervention",
abstract = "Background and aims: Angiotensin-converting-enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB) are known to be beneficial for either non-ST-segment elevation myocardial infarction (NSTEMI) patients or diabetes mellitus (DM) patients. However, the comparative efficacy of ACEI versus ARB in patients with NSTEMI and DM is unclear. The aim of this study was to compare the protective efficacy of ACEI versus ARB in patients with NSTEMI and DM, who underwent percutaneous coronary intervention (PCI) with drug-eluting stents (DES). Methods: Among 53,281 patients enrolled in the nationwide Korea Acute Myocardial Infarction Registry, 3426 patients with NSTEMI and DM, who were treated with renin-angiotensin system (RAS) inhibitors, had undergone successful PCI with DESs. They were classified into two groups: ACEI group (N = 2076), and ARB group (N = 1350). Individual major clinical outcomes and major adverse cardiac events (MACE), the composite of total death, myocardial infarction (MI), and revascularization were compared between the two groups for up to two years. Results: After propensity score-matching analysis, two propensity-matched groups (1103 pairs, total = 2206) were generated, and the baseline characteristics were balanced. Although all causes of death and recurrent MI were not different between the two groups, the incidence of revascularization (4.0{\%} vs. 7.1{\%}; p = 0.002), including target vessel (2.3{\%} vs. 5.0; p = 0.002), and MACE (8.7{\%} vs. 12.5{\%}, p = 0.008), were lower in the ACEI group than the ARB group at two-year follow-up. Conclusions: Compared with ARB, no beneficial effects of ACEI on all causes of death, cardiac death, or recurrence of MI were observed, but ACEI reduced the incidence of revascularization and MACE in this population. Thus, well-designed trials with a larger population are needed to confirm these results.",
keywords = "Angiotensin II receptor blockers, Angiotensin-converting-enzyme inhibitors, Diabetes mellitus, Myocardial infarction, Non-ST-Segment elevation myocardial infarction",
author = "{Other Korea Acute Myocardial Infarction Registry (KAMIR) investigators} and Byun, {Jae Kyeong} and Choi, {Byoung Geol} and Seung-Woon Rha and Choi, {Se Yeon} and Jeong, {Myung Ho}",
year = "2018",
month = "10",
day = "1",
doi = "10.1016/j.atherosclerosis.2018.08.038",
language = "English",
volume = "277",
pages = "130--135",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with diabetes mellitus and non-ST-segment elevation myocardial infarction who underwent successful percutaneous coronary intervention

AU - Other Korea Acute Myocardial Infarction Registry (KAMIR) investigators

AU - Byun, Jae Kyeong

AU - Choi, Byoung Geol

AU - Rha, Seung-Woon

AU - Choi, Se Yeon

AU - Jeong, Myung Ho

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Background and aims: Angiotensin-converting-enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB) are known to be beneficial for either non-ST-segment elevation myocardial infarction (NSTEMI) patients or diabetes mellitus (DM) patients. However, the comparative efficacy of ACEI versus ARB in patients with NSTEMI and DM is unclear. The aim of this study was to compare the protective efficacy of ACEI versus ARB in patients with NSTEMI and DM, who underwent percutaneous coronary intervention (PCI) with drug-eluting stents (DES). Methods: Among 53,281 patients enrolled in the nationwide Korea Acute Myocardial Infarction Registry, 3426 patients with NSTEMI and DM, who were treated with renin-angiotensin system (RAS) inhibitors, had undergone successful PCI with DESs. They were classified into two groups: ACEI group (N = 2076), and ARB group (N = 1350). Individual major clinical outcomes and major adverse cardiac events (MACE), the composite of total death, myocardial infarction (MI), and revascularization were compared between the two groups for up to two years. Results: After propensity score-matching analysis, two propensity-matched groups (1103 pairs, total = 2206) were generated, and the baseline characteristics were balanced. Although all causes of death and recurrent MI were not different between the two groups, the incidence of revascularization (4.0% vs. 7.1%; p = 0.002), including target vessel (2.3% vs. 5.0; p = 0.002), and MACE (8.7% vs. 12.5%, p = 0.008), were lower in the ACEI group than the ARB group at two-year follow-up. Conclusions: Compared with ARB, no beneficial effects of ACEI on all causes of death, cardiac death, or recurrence of MI were observed, but ACEI reduced the incidence of revascularization and MACE in this population. Thus, well-designed trials with a larger population are needed to confirm these results.

AB - Background and aims: Angiotensin-converting-enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB) are known to be beneficial for either non-ST-segment elevation myocardial infarction (NSTEMI) patients or diabetes mellitus (DM) patients. However, the comparative efficacy of ACEI versus ARB in patients with NSTEMI and DM is unclear. The aim of this study was to compare the protective efficacy of ACEI versus ARB in patients with NSTEMI and DM, who underwent percutaneous coronary intervention (PCI) with drug-eluting stents (DES). Methods: Among 53,281 patients enrolled in the nationwide Korea Acute Myocardial Infarction Registry, 3426 patients with NSTEMI and DM, who were treated with renin-angiotensin system (RAS) inhibitors, had undergone successful PCI with DESs. They were classified into two groups: ACEI group (N = 2076), and ARB group (N = 1350). Individual major clinical outcomes and major adverse cardiac events (MACE), the composite of total death, myocardial infarction (MI), and revascularization were compared between the two groups for up to two years. Results: After propensity score-matching analysis, two propensity-matched groups (1103 pairs, total = 2206) were generated, and the baseline characteristics were balanced. Although all causes of death and recurrent MI were not different between the two groups, the incidence of revascularization (4.0% vs. 7.1%; p = 0.002), including target vessel (2.3% vs. 5.0; p = 0.002), and MACE (8.7% vs. 12.5%, p = 0.008), were lower in the ACEI group than the ARB group at two-year follow-up. Conclusions: Compared with ARB, no beneficial effects of ACEI on all causes of death, cardiac death, or recurrence of MI were observed, but ACEI reduced the incidence of revascularization and MACE in this population. Thus, well-designed trials with a larger population are needed to confirm these results.

KW - Angiotensin II receptor blockers

KW - Angiotensin-converting-enzyme inhibitors

KW - Diabetes mellitus

KW - Myocardial infarction

KW - Non-ST-Segment elevation myocardial infarction

UR - http://www.scopus.com/inward/record.url?scp=85053033619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053033619&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2018.08.038

DO - 10.1016/j.atherosclerosis.2018.08.038

M3 - Article

C2 - 30212681

AN - SCOPUS:85053033619

VL - 277

SP - 130

EP - 135

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

ER -